Evernorth announces Humira biosimilar available at $0 out of pocket for Accredo patients in June

April 25, 24

Understanding hereditary angioedema (HAE)

Breaking down what plan sponsors should know about HAE, its challenges and therapies.

Lesley D'Albini, PharmD, March 27, 24

The importance of a clinical-first approach to formulary development

The clinical efficacy of a drug must always take priority over any other considerations when developing formularies.

Andy Behm, PharmD, BCGP, February 05, 24

Fighting nonadherence with integrated data insights

Plan sponsors can solve for medication nonadherence among their members via proactive intervention and tailored care coordination.

December 06, 23

How to improve specialty drug adherence for patients with inflammatory conditions

To mitigate nonadherence for inflammatory condition treatments, plan sponsors should adopt a multifaceted approach that combines clinical protocols and value-based solutions.

Mary Dorholt, PharmD, November 03, 23